Carlisle Companies

CSL on NYSE. Carlisle Companies sells blood plasma medicines and vaccines to hospitals and patients. Market value $13.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
6.6%high

For every $100 of what the whole company costs, it produced $6.59 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
15.1×full

You pay 15.1 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
18.2%five-year median

Each dollar kept in the business earns 18 cents a year. Above 10 is good.

Quality score: 93 of 100. Price score: 91 of 100. Our list needs 70 on quality and 60 on price.

$330.98 a share, 13% above its 1-year low

Over the past year the price has ranged from $293.43 to $432.91.

Dividend: 1.4% a year

Paid every year for at least 5 years

Prices from Monday’s close (5 October).

Five years of cash, in billions

0.3
0.8
1.1
0.9
1.0
0.9
2021202220232024202512 monthsto Jun '26
Revenue
$3.8bn$5.4bn$4.6bn$5.0bn$5.0bn
Operating margin
14.9%22.1%21.4%22.8%20.0%
Debt to equity
1.110.850.810.771.61
Shares outstanding
0.05bn0.05bn0.05bn0.04bn0.04bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)6 of 9
  • Profit backed by cash (accruals)Yes
  • Debt1.61× equity
  • Revenue growth, five yearsSlow, 4.8% a year
  • Buying back its own sharesYes, 23% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.6 billion last quarter, up 8% on a year ago.
  • Profit: $255 million, about the same as a year ago.
  • It keeps 20 cents of each $1 of sales as operating profit, down from 21 cents a year earlier.
  • Spare cash over the past 12 months: $867 million, up from $859 million.
  • 7% fewer shares than a year ago. Each share owns a bit more of the company.
  • Debt is $2.2 billion more than cash, up from $1.8 billion a year ago.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$1.3bn
December 2024$1.1bn
March 2025$1.1bn
June 2025$1.4bn
September 2025$1.3bn
December 2025$1.1bn
March 2026$1.1bn
June 2026$1.6bn
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$244m
December 2024$163m
March 2025$143m
June 2025$256m
September 2025$214m
December 2025$127m
March 2026$128m
June 2026$255m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
13 February 2026
Next quarterly (estimated, 10-Q)
29 October 2026

Who owns it

13 long-term investors we follow own it, unchanged from 13 last quarter. 796 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 5 sold $28m.

  • Easton Andrew C
    VP & Chief Accounting Officer
    Sold
    Date
    19 February 2026
    Shares
    233
    Price
    $407.57
    Value
    $94,964
  • Schwar Stephen
    Vice Chair of CCM
    Sold
    Date
    12 February 2026
    Shares
    6,049
    Price
    $417.36
    Value
    $3m
  • SMITH DAVID W
    VP, Sustainability
    Sold
    Date
    10 February 2026
    Shares
    1,800
    Price
    $414.05
    Value
    $745,290
  • Zdimal Kevin P
    VP & Chief Financial Officer
    Sold
    Date
    10 February 2026
    Shares
    24,180
    Price
    $408.04
    Value
    $10m
  • KOCH D CHRISTIAN
    Chair, President & CEO
    Sold
    Date
    10 February 2026
    Shares
    36,260
    Price
    $413.38
    Value
    $15m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 13 Feb 2026, plus the 10-Q filed 30 Jul 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • The Company could face product liability claims, and we may not have sufficient insurance to cover those claims.

    Could happen
    Our building products are used in a wide variety of commercial, residential and industrial applications. We face an inherent risk of exposure to product liability or other claims in the event our products are alleged to be defective or that the use of our products is alleged to have resulted in harm to others or their property. If product liability lawsuits against us are successful, it could have an adverse impact on our financial condition and results of operations. Moreover, any such lawsuits, whether or not successful, could result in adverse publicity to us, which could harm our reputation and cause our sales to decline. We maintain insurance coverage to protect us against product liability Table of Content s claims, but that coverage may not be adequate to cover all claims that may arise, or we may not be able to maintain adequate insurance coverage in the future at an acceptable cost. Any liability not covered by insurance or that exceeds our established reserves could materially and adversely impact our business, financial condition and results of operations.
    Read more
  • The development and introduction of new products, or the failure to do so, could have a material adverse effect on our business, financial condition, results of operations or cash flows.

    Could happen
    A key pillar of the Company’s Vision 2030 strategic plan is driving growth through continued investment in new product innovation. Our likelihood of success in investing in new products must be considered in light of the expenses, difficulties and delays frequently encountered in connection with the early phases of new product development, including the difficulties involved in obtaining permits and regulatory approvals, planning and constructing new manufacturing facilities, and establishing, maintaining or expanding customer relationships. While Table of Content s we strive to introduce new products, our efforts to develop and market new products may be unsuccessful or unprofitable, which could adversely affect our business, financial condition, results of operations or cash flows.
    Read more
  • The Company could be adversely affected by any significant damage to, or prolonged disruption of, our manufacturing facilities.

    Could happen
    The Company has made substantial investments in manufacturing facilities, and many products are produced at a limited number of locations. These facilities could be materially damaged or operations at these facilities could be materially disrupted by natural disasters, such as floods, tornados, hurricanes, fires and earthquakes, as well as governmental or administrative actions, regulatory issues, civil unrest, industrial accidents, unavailability or excessively high cost of raw materials, mechanical equipment failure, human error, cybersecurity breaches, widespread health emergencies, theft, sabotage or other reasons. We could incur uninsured losses and liabilities arising from such events, including damage to our reputation, or suffer material losses in operational capacity, which could have a material adverse impact on our business, financial condition, results of operations or cash flows.
    Read more
  • The Company’s growth strategy is partially dependent on the acquisition and successful integration of other businesses.

    Could happen
    A key pillar of the Company’s Vision 2030 strategic plan is building scale with synergistic acquisitions. When companies become available for purchase, the process is often highly competitive, which tends to result in relatively high valuations for the target company. There can be no assurance that the Company will be able to continue to identify, negotiate and finance suitable acquisitions at values the Company considers reasonable.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.